Safety and Efficacy of RNAi Therapy for Transthyretin Amyloidosis
Safety and Efficacy of RNAi Therapy for Transthyretin Amyloidosis
Publisher:
New England Journal of Medicine
Date published:
2013
Record type:
Journal Title:
The New England Journal of Medicine
Source:
The New England Journal of Medicine, Vol. 369, No. 9, August 29, 2013, pp. 819-829
Abstract:
Transthyretin amyloidosis is largely caused by synthesis of mutant transthyretin in the liver and deposition of transthyretin in other organs. A therapeutic approach mediated by RNA interference resulted in reduced transthyretin levels in affected patients and in controls.
Language:
Catagory URL:
CITATION: Coelho T. [etal]. Safety and Efficacy of RNAi Therapy for Transthyretin Amyloidosis . : New England Journal of Medicine , 2013. The New England Journal of Medicine, Vol. 369, No. 9, August 29, 2013, pp. 819-829 - Available at: https://library.au.int/safety-and-efficacy-rnai-therapy-transthyretin-amyloidosis-4